Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease therapies to its pipeline. Merck will pay $47 per share of SpringWorks, making the deal worth $3.9 billion…
Germany’s Merck KGaA has agreed to buy SpringWorks Therapeutics, adding the US biotech’s portfolio of cancer and rare disease therapies to its pipeline. Merck will pay $47 per share of SpringWorks, making the deal worth $3.9 billion…